Innovation Activities and Developments

Innovation Activities and Developments

Learn more about the discoveries and innovations that take place at MSK every day. 

11 News Items found
William Tap
MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program
Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
Rick Peng announcing launch of 2025 iHub Challenge Cohort
MSK iHub Challenge 2025 Cohort Now Open for Applications
Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply.
Eileen Flowers, PhD
MSK Therapeutics Accelerator Launches New Cohort Program
Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.
Saad Nadeem, PhD, Assistant Attending Computer Scientist
MSK Partners with PathPresenter to Integrate New AI Module for Oncology Research
Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research.
Memorial Sloan Kettering Cancer Center and AWS to Accelerate AI-Driven Cancer Innovation
Memorial Sloan Kettering Cancer Center and AWS to Accelerate AI-Driven Cancer Innovation
Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
MSK’s WOUND-Q™ Questionnaire is FDA-Qualified as a Medical Device Development Tool
MSK’s WOUND-Q™ Questionnaire is FDA-Qualified as a Medical Device Development Tool
The U.S. Food and Drug Administration (FDA) qualified MSK’s WOUND-Q™ questionnaire as a Medical Device Development Tool (MDDT) in November 2024.
Michael Buckley
MSK Presents Significant Data Study Findings to FDA
The global clinical research community is facing a clear imperative to move beyond traditional manual data management methods in order to improve data capture, integrity, and exchange, while pursuing other related efficiencies.
Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024.
Arcascope Joins the MSK Innovation Hub
Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024.
MSK Joins Global Clinical Research Innovation Task Force
MSK Joins Global Clinical Research Innovation Task Force
Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration.
Meet MSK Evidence-Based Practice (EBP) Consulting
An expert team within the Nursing Department at MSK has recently launched a new program called MSK Evidence-based (EBP) Consulting.